Actinomycetales infections and treatment
Actinomycetales infections and treatment is a research topic within Microbiology. Science Explorer counts 7.8k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the clinical and molecular aspects of Nocardiosis, including Nocardia spp., actinomycosis, mycetoma, antimicrobial susceptibility, transplant recipients, genomic sequencing, taxonomy, epidemiology, and clinical features. It provides insights into the risk factors, characteristics, outcomes, and management of Nocardia infections in various patient populations.
- Nocardia spp.
- Actinomycosis
- Mycetoma
- Antimicrobial Susceptibility
- Transplant Recipients
- Genomic Sequencing
- Taxonomy
- Epidemiology
- Clinical Features
- Diagnosis
- Research works
- 7.8k fractional, since 1950
- In the world top 10%
- 784 per year above
- Top-10% rate
- 10.1% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- +20% the tick is no change
- Largest producer
United States
32% of the 10 largest, 2022-now
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Actinomycetales infections and treatment research?
By volume, the United States and China publish the most (306 and 191 works in 2022-now).
By volume, 2022-now
- 1
United States 306 works
- 2
China 191 works
- 3
India 166 works
- 4
Japan 85 works
- 5
Brazil 48 works
- 6
Spain 40 works
- 7
United Kingdom 38 works
- 8
Germany 32 works
- 9
Italy 31 works
- 10
France 31 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Actinomycetales infections and treatment research?
By volume in 2022-now, Mayo Clinic publishes the most Actinomycetales infections and treatment research, followed by All India Institute of Medical Sciences and University of Khartoum.
By volume, 2022-now
- 1
Mayo Clinic
United States 19 works
- 2
All India Institute of Medical Sciences
India 18 works
- 3
University of Khartoum
Sudan 13 works
- 4
Capital Medical University
China 6 works
- 5
Zhejiang University
China 6 works
- 6
Erasmus University Rotterdam
Netherlands 6 works
- 7
Universidade de São Paulo
Brazil 5 works
- 8
Sichuan University
China 5 works
- 9
United States Department of Veterans Affairs
United States 5 works
- 10
Banaras Hindu University
India 5 works
Who are the leading researchers in Actinomycetales infections and treatment?
The most-cited researchers publishing on Actinomycetales infections and treatment include Jun Wang, Patrizio Lancellotti and Didier Raoult.
- 1
Jun Wang
China 340k citations
- 2
Patrizio Lancellotti
Belgium 245k citations
- 3
Didier Raoult
France 232k citations
- 4
Ziad Ahmed Memish
Saudi Arabia 224k citations
- 5
Bernard Iung
France 203k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Actinomycetales infections and treatment research done?
The largest centres of Actinomycetales infections and treatment research in 2022-now are Beijing (China), Tokyo (Japan), Khartoum (Sudan) and New Delhi (India).
Where is the best place to study Actinomycetales infections and treatment?
Among universities, judged by research, University of Khartoum and All India Institute of Medical Sciences score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | University of Khartoum |
55.0 | 21.2% | 167.1× | 13 | +0.2% |
| 2 | All India Institute of Medical Sciences |
39.5 | 3.3% | 13.2× | 18 | +18.0% |
Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.
Every institution in Actinomycetales infections and treatment, country by countryIs Actinomycetales infections and treatment research growing?
Output in 2022-2025 was 20% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Actinomycetales infections and treatment.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Actinomycetales infections and treatment as a percentage of every work published that year, 0.0060% in 2024.
Fractional works of Actinomycetales infections and treatment over all fractional works that year. How the balance of science has shifted.
How much of it reaches the world top 10%
Year by year.
Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.
Discussion
Ask a question or share a note about Actinomycetales infections and treatment. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.